Imagine a child born in a family with a rare disease, whose treatment would cost more than 17 crore for a single dose. The ...
Gene therapy is linked to better nonmotor outcomes in spinal muscular atrophy type 1 compared to first-line nusinersen, new ...
As their 8-month-old daughter prepares for gene therapy treatment, a Coon Rapids family is bracing for three months of ...
Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy ...
Novartis is seeking to repurpose its investigational oral spinal muscular atrophy (SMA) drug branaplam to treat Huntington's disease, the Swiss drugmaker said on Wednesday, as it plans a clinical ...
Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also got the FDA no-go ...
In a huge setback for Swiss pharma major Roche, the Supreme Court on Friday dismissed its petition challenging a Delhi High ...
In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to ...
The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback